Hit and lead criteria in drug discovery for infectious diseases of the developing world

@article{Katsuno2015HitAL,
  title={Hit and lead criteria in drug discovery for infectious diseases of the developing world},
  author={K. Katsuno and J. Burrows and K. Duncan and R. V. Huijsduijnen and T. Kaneko and K. Kita and C. Mowbray and D. Schmatz and P. Warner and B. Slingsby},
  journal={Nature Reviews Drug Discovery},
  year={2015},
  volume={14},
  pages={751-758}
}
Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for… Expand
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
Hit Generation in TB Drug Discovery: From Genome to Granuloma
Actives from MMV Open Access Boxes? A suggested way forward
Integrative Multi-Kinase Approach for the Identification of Potent Antiplasmodial Hits
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
Innovative lead discovery strategies for tropical diseases
Challenges in antimalarial drug discovery.
Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches
  • I. Gilbert
  • Biology, Medicine
  • Journal of medicinal chemistry
  • 2013
Chagas Disease Drug Discovery
  • E. Chatelain
  • Biology, Medicine
  • Journal of biomolecular screening
  • 2015
...
1
2
3
4
5
...